Vemlidy and Besivo enters Severance Hospital at the same time

Published: 2017-11-27 16:28:00
Updated: 2017-11-27 13:34:22

‘Vemlidy,’ a Gilead Sciences/Yuhan Corporation’s chronic hepatitis B treatment whose health insurance benefits have been applied from 1 November, and Ildong Pharmaceutical’s ‘Besivo’ entered in Severance Hospital.

Severance Hospital approved Vemlidy and Besivo for a prescription code at its rece...


- Email service daily and homepage access.
  1. $300 per month. ($3,240 per year)
  2. 5 Email holders per each company.
  3. Anual contract base.

Original Korean

Most Read News

Address: 295-1, Chungpa-Ro, Yongsan-Gu, Korea
Phone: 02-3270-0114 | Fax: 02-3270-0129 | Email:

Copyright © Yakup Shinmoon, Inc. All Rights Reserved.